NewsBenzingaVaxcyte表示，VAX-31（31价肺炎球菌结合疫苗候选产品）在OPUS-1关键性成人III期试验中的顶线结果显示，在所研究的各年龄组中，相较于Prevnar 20和/或Capvaxive，已达到所有预先设定的主要终点 Vaxcyte表示，VAX-31（31价肺炎球菌结合疫苗候选产品）在OPUS-1关键性成人III期试验中的顶线结果显示，在所研究的各年龄组中，相较于Prevnar 20和/或Capvaxive，已达到所有预先设定的主要终点 Benzinga 2026.10.05 10:06 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Overweight on Essential Properties, Lowers Price Target to $30 Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $13.5 Morgan Stanley Maintains Underweight on Simmons First Ntl, Raises Price Target to $27 Wells Fargo Maintains Equal-Weight on EPR Properties, Lowers Price Target to $56 Analyst Sees Billions in Walmart's Next Big Advertising Opportunity Morgan Stanley Maintains Equal-Weight on Red Rock Resorts, Lowers Price Target to $59
